TG Therapeutics (TGTX) Competitors

$42.65 +0.11 (+0.26%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$42.58 -0.07 (-0.17%)

As of 04:00 AM Eastern

TGTX vs. BNTX, INSM, MRNA, ROIV, and VTRS

Should you buy TG Therapeutics stock or one of its competitors? MarketBeat compares TG Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TG Therapeutics include BioNTech (BNTX), Insmed (INSM), Moderna (MRNA), Roivant Sciences (ROIV), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does TG Therapeutics compare to BioNTech?

TG Therapeutics (NASDAQ:TGTX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to BioNTech's net margin of -44.39%. TG Therapeutics' return on equity of 88.73% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
BioNTech	-44.39%	-5.30%	-4.62%

TG Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	10.59	$447.18M	$2.86	14.91
BioNTech	$3.25B	7.18	-$1.29B	-$5.88	N/A

TG Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, TG Therapeutics and TG Therapeutics both had 13 articles in the media. TG Therapeutics' average media sentiment score of 0.70 beat BioNTech's score of 0.39 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics currently has a consensus target price of $52.50, indicating a potential upside of 23.09%. BioNTech has a consensus target price of $130.60, indicating a potential upside of 41.60%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Summary

TG Therapeutics beats BioNTech on 10 of the 15 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

TG Therapeutics (NASDAQ:TGTX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Insmed	-144.44%	-130.11%	-51.57%

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	10.59	$447.18M	$2.86	14.91
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A

TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, Insmed had 31 more articles in the media than TG Therapeutics. MarketBeat recorded 44 mentions for Insmed and 13 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.70 beat Insmed's score of 0.56 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	15 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

TG Therapeutics currently has a consensus target price of $52.50, indicating a potential upside of 23.09%. Insmed has a consensus target price of $210.95, indicating a potential upside of 78.79%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

TG Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Moderna had 29 more articles in the media than TG Therapeutics. MarketBeat recorded 42 mentions for Moderna and 13 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.70 beat Moderna's score of 0.62 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	21 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna presently has a consensus target price of $35.73, indicating a potential downside of 29.13%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 23.09%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

TG Therapeutics has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	10.29	-$2.82B	-$8.15	N/A
TG Therapeutics	$616.29M	10.59	$447.18M	$2.86	14.91

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Moderna on 13 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for TG Therapeutics and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.16 beat TG Therapeutics' score of 0.70 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences presently has a consensus target price of $30.55, indicating a potential upside of 4.55%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 23.09%. Given TG Therapeutics' higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Roivant Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	719.89	-$171.98M	-$1.17	N/A
TG Therapeutics	$616.29M	10.59	$447.18M	$2.86	14.91

TG Therapeutics has a net margin of 65.95% compared to Roivant Sciences' net margin of -6,079.94%. TG Therapeutics' return on equity of 88.73% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Viatris?

TG Therapeutics (NASDAQ:TGTX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

TG Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	10.59	$447.18M	$2.86	14.91
Viatris	$14.30B	1.41	-$3.51B	-$0.26	N/A

TG Therapeutics presently has a consensus price target of $52.50, indicating a potential upside of 23.09%. Viatris has a consensus price target of $15.71, indicating a potential downside of 9.53%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe TG Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Viatris	-2.04%	19.04%	7.62%

In the previous week, Viatris had 7 more articles in the media than TG Therapeutics. MarketBeat recorded 20 mentions for Viatris and 13 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.70 beat Viatris' score of 0.60 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	2 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Viatris on 13 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.51B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	14.91	18.67	21.03	25.58
Price / Sales	10.59	301.13	552.98	78.84
Price / Cash	15.18	122.51	42.94	55.34
Price / Book	11.19	6.75	9.82	6.66
Net Income	$447.18M	$24.11M	$3.55B	$333.63M
7 Day Performance	-0.88%	-0.53%	-0.53%	-0.11%
1 Month Performance	23.41%	0.34%	1.20%	3.94%
1 Year Performance	27.69%	78.62%	41.23%	36.07%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	4.2143 of 5 stars	$42.65 +0.3%	$52.50 +23.1%	+27.8%	$6.51B	$616.29M	14.91	290
BNTX BioNTech	3.8 of 5 stars	$93.34 -0.8%	$131.60 +41.0%	-2.4%	$23.80B	$3.25B	N/A	7,807	Analyst Forecast Buyback Announcement
INSM Insmed	3.1505 of 5 stars	$103.89 +2.5%	$211.86 +103.9%	+79.6%	$21.97B	$606.42M	N/A	1,664	Trending News Earnings Report Analyst Forecast Analyst Revision High Trading Volume
MRNA Moderna	1.4631 of 5 stars	$52.88 -2.7%	$35.73 -32.4%	+97.8%	$21.57B	$1.94B	N/A	4,700	Trending News High Trading Volume
ROIV Roivant Sciences	2.4624 of 5 stars	$28.96 +1.4%	$30.55 +5.5%	+171.6%	$20.44B	$29.05M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. BNTX, INSM, MRNA, ROIV, and VTRS

How does TG Therapeutics compare to BioNTech?

Summary

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to Moderna?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Summary

How does TG Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. BNTX, INSM, MRNA, ROIV, and VTRS

How does TG Therapeutics compare to BioNTech?

Do insiders and institutionals have more ownership in TGTX or BNTX?

Is TGTX or BNTX more profitable?

Which has better valuation & earnings, TGTX or BNTX?

Which has more risk and volatility, TGTX or BNTX?

Does the media prefer TGTX or BNTX?

Do analysts prefer TGTX or BNTX?

Summary

How does TG Therapeutics compare to Insmed?

Do institutionals and insiders have more ownership in TGTX or INSM?

Is TGTX or INSM more profitable?

Which has preferable valuation and earnings, TGTX or INSM?

Which has more volatility & risk, TGTX or INSM?

Does the media favor TGTX or INSM?

Do analysts prefer TGTX or INSM?

Summary

How does TG Therapeutics compare to Moderna?

Do insiders & institutionals have more ownership in MRNA or TGTX?

Does the media refer more to MRNA or TGTX?

Do analysts recommend MRNA or TGTX?

Which has more risk and volatility, MRNA or TGTX?

Which has higher earnings & valuation, MRNA or TGTX?

Is MRNA or TGTX more profitable?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Do insiders & institutionals have more ownership in ROIV or TGTX?

Does the media refer more to ROIV or TGTX?

Do analysts recommend ROIV or TGTX?

Which has more risk and volatility, ROIV or TGTX?

Which has higher earnings & valuation, ROIV or TGTX?

Is ROIV or TGTX more profitable?

Summary

How does TG Therapeutics compare to Viatris?

Which has stronger earnings and valuation, TGTX or VTRS?

Do analysts recommend TGTX or VTRS?

Is TGTX or VTRS more profitable?

Does the media refer more to TGTX or VTRS?

Which has more risk & volatility, TGTX or VTRS?

Do institutionals & insiders have more ownership in TGTX or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools